These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 35238725)

  • 1. Clinical pharmacology considerations for the approval of belimumab for the treatment of adult patients with active lupus nephritis: A regulatory perspective.
    Liu T; Neuner R; Thompson A; Pottackal G; Petullo D; Liu J; Nikolov N; Sahajwalla C; Doddapaneni S; Chen J
    Lupus; 2022 Apr; 31(4):424-432. PubMed ID: 35238725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program.
    Yapa SW; Roth D; Gordon D; Struemper H
    Lupus; 2016 Nov; 25(13):1448-1455. PubMed ID: 27072354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapolation of the Efficacy and Pharmacokinetics of Belimumab to Support its Use in Children with Lupus Nephritis.
    Dimelow R; Liefaard L; Green Y; Tomlinson R
    Clin Pharmacokinet; 2024 Sep; 63(9):1313-1326. PubMed ID: 39320441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Belimumab in Patients with Lupus Nephritis: Open-Label Extension of BLISS-LN Study.
    Furie R; Rovin BH; Houssiau F; Contreras G; Teng YKO; Curtis P; Green Y; Okily M; Madan A; Roth DA
    Clin J Am Soc Nephrol; 2022 Nov; 17(11):1620-1630. PubMed ID: 36302567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belimumab for the treatment of pediatric patients with lupus nephritis.
    Stohl W; Kwok A
    Expert Opin Biol Ther; 2023 Mar; 23(3):243-251. PubMed ID: 36750049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort.
    Gatto M; Saccon F; Andreoli L; Bartoloni E; Benvenuti F; Bortoluzzi A; Bozzolo E; Brunetta E; Canti V; Cardinaletti P; Ceccarelli F; Ciccia F; Conti F; De Marchi G; de Paulis A; De Vita S; Emmi G; Faggioli P; Fasano S; Fredi M; Gabrielli A; Gasparotto M; Gerli R; Gerosa M; Govoni M; Gremese E; Laria A; Larosa M; Mosca M; Orsolini G; Pazzola G; Petricca L; Ramirez GA; Regola F; Rossi FW; Rossini M; Salvarani C; Scarpato S; Tani C; Tincani A; Ubiali T; Urban ML; Zen M; Doria A; Iaccarino L
    J Autoimmun; 2021 Nov; 124():102729. PubMed ID: 34600347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab.
    Simeoni M; Yang S; Tompson DJ; Dimelow R
    J Pharmacokinet Pharmacodyn; 2024 Jun; 51(3):289-301. PubMed ID: 38551711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial.
    Anders HJ; Furie R; Malvar A; Zhao MH; Hiromura K; Weinmann-Menke J; Green Y; Jones-Leone A; Negrini D; Levy RA; Lightstone L; Tanaka Y; Rovin BH
    Nephrol Dial Transplant; 2023 Nov; 38(12):2733-2742. PubMed ID: 37463054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis.
    Li H; Chen C; Yang H; Tu J
    Eur J Pediatr; 2024 Sep; 183(9):3987-3995. PubMed ID: 38940925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.
    Rovin BH; Furie R; Teng YKO; Contreras G; Malvar A; Yu X; Ji B; Green Y; Gonzalez-Rivera T; Bass D; Gilbride J; Tang CH; Roth DA
    Kidney Int; 2022 Feb; 101(2):403-413. PubMed ID: 34560137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10 Years of belimumab experience: What have we learnt?
    Levy RA; Gonzalez-Rivera T; Khamashta M; Fox NL; Jones-Leone A; Rubin B; Burriss SW; Gairy K; Maurik AV; Roth DA
    Lupus; 2021 Oct; 30(11):1705-1721. PubMed ID: 34238087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient).
    Binda V; Trezzi B; Del Papa N; Beretta L; Frontini G; Porata G; Fabbrini P; Pozzi MR; Messa P; Sinico RA; Moroni G
    J Nephrol; 2020 Oct; 33(5):1019-1025. PubMed ID: 32002799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
    Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA
    N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of Belimumab combined with standard therapy in severe active lupus nephritis requiring kidney replacement therapy: A case report and literature review.
    Zhang C; Zeng M; Ge Y; Liu K; Xing C; Mao H
    Front Immunol; 2022; 13():977377. PubMed ID: 36172377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis.
    Zhang H; Chen J; Zhang Y; Zhao N; Xu D
    Ren Fail; 2023 Dec; 45(1):2207671. PubMed ID: 37194710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
    Liu D; Zhou Q; Wang D; Qu Y; Guo Q; Wen J; Yu Q; Ai J
    Lupus; 2022 Oct; 31(12):1456-1467. PubMed ID: 35960182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.